More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on 
claims, etc.
No doubt the FDA probably has one busy IT department after many years and now having to catch up to take advantage of the information technology age, it's all about software (and saving money and cutting costs). Medco will deliver a series of reports to the FDA about pharmacogenomic testing. Almost 30 percent of all medications are metabolized by one enzyme (CYP2D6) and this can help in finding or eliminating the correct drug of choice for the treatment plan. BD
The two-year agreement calls for Medco to deliver reports to the FDA about pharmacogenomic testing, including physician participation in such testing and the usefulness of testing in prescribing medicines. Medco said it will derive its reports from clinical settings, examining, for example, whether physicians will be willing to change dosages based on a genetic test result. Medco's database of pharmacy claims will supply a large portion of the data to be used in reports to the FDA, the company said.
"Our payer base, the people who pay the bill for prescription drug benefits, are looking for management. They're looking for appropriateness of care, they don't want to throw their prescription dollars down the drain" for drugs that won't work, Epstein said. "That's right up our strike lane."
Medco Health, FDA To Study Genetic Testing For Medications
0 comments :
Post a Comment